This post was originally published on this site
Oncology diagnostics firm Oncocyte Corp. announced Tuesday a rebranding and relocation of the company’s headquarters from Irvine to Nashville, Tennessee.
The rebranded company is now called Insight Molecular Diagnostics Inc. Before the market opens June 18, its common stock (Nasdaq: OCX) will begin to trade under the new Nasdaq ticker, “IMDX.”
The company said the name change and out-of-state move reflect its expanded focus beyond oncology, including its strategic push into transplant medicine. Nashville is also home to the company’s CLIA-certified lab and “a growing hub for healthcare innovation,” the company said.
“We believe that iMDx is just getting started in its value-creation journey, and that these changes reflect our renewed priorities and focus,” iMDx Chief Financial Officer Andrea James said in a statement released Tuesday. “We believe the rebranding and design of the new logo symbolically support our aim to put doctors, laboratory technicians, and researchers at the center of what we do, to equip them with more diagnostic tools to better serve their patients.”